Pfizer (PFE, $36.73) says coronavirus vaccine is 95% effective
Pfizer Inc. announce that the coronavirus vaccine that is has developed with German partner, BioNTech , has a 95% efficacy rate, in its complete results from a late-stage trial. The result is an improvement from the interim results of efficacy rate of 90% last month, which was based a cohort of around 94 patients.
The latest result is consistent across all age and race demographics and based on a total case cohort of 170, according to Pfizer.
A few days ago, Moderna published a efficacy rated of 94.5% of its vaccine, based on early look of its late-stage trial.
Pfzer and BioNTech said they the will apply for Emergency Use Authorization from the U.S. Food & Drug Administration in the coming days. They will produce 50 million does by the end of this year, and 1.3 billion doses by next year.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PFE in -0.50% downward trend, declining for three consecutive days on September 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PFE declined for three days, in 183 of 323 cases, the price declined further within the following month. The odds of a continued downward trend are 57%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for PFE moved out of overbought territory on September 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In 13 of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at 50%.
The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PFE as a result. In 47 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 54%.
The Moving Average Convergence Divergence Histogram (MACD) for PFE turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 23 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
PFE broke above its upper Bollinger Band on August 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 50-day moving average for PFE moved above the 200-day moving average on August 27, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +1.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in 143 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 53%.
The Aroon Indicator entered an Uptrend today. In 91 of 192 cases where PFE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 47%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.855) is normal, around the industry mean (18.892). P/E Ratio (36.474) is within average values for comparable stocks, (31.670). Projected Growth (PEG Ratio) (12.679) is also within normal values, averaging (5.721). PFE's Dividend Yield (0.062) is considerably higher than the industry average of (0.029). P/S Ratio (2.492) is also within normal values, averaging (3.991).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor
Advertisement